[A19-35] Venetoclax (chronic lymphocytic leukaemia; combination with rituximab) - Addendum to Commission A18-81
Last updated 16.05.2019
Commission awarded on 09.04.2019 by the Federal Joint Committee (G-BA).
Adult patients with chronic lymphocytic leukaemia with at least one prior therapy and without 17p deletion and/or TP53 mutation who are candidates for chemoimmunotherapy
Study MURANO: effects only in favour of venetoclax with rituximab in comparison with bendamustine with rituximab; derivation of an added benefit not possible due to deviation from appropriate comparator therapy, however
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
|A18-81||Venetoclax (chronic lymphocytic leukaemia) - Benefit assessment according to §35a Social Code Book V||Commission completed|